There is an unmet need to develop approaches to target atherosclerotic plaque which would allow drugs to home to and penetrate into the plaque intima. Our studies address these challenges, they explore the use of a novel peptide called XY to specifically target fibrous plaques and establish a biologic agent, CLM-XY, as a potent anti-atherosclerotic drug.
When injected intravenously into ApoE-null atherosclerotic mice, XY accumulated in, the interior of atherosclerotic plaques . This specific binding of XY to fibrous plaques in mice was also highly conserved in human plaques.